Exploring RE-CIRCUIT

Join Dr Hugh Calkins for a discussion of his groundbreaking paper: Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey

Highlights report

You can recap the learnings of this journal club by reading the short, comprehensive highlights report which details the key findings of the discussion.

Access highlights report

Speaker

Dr Hugh Calkins

John Hopkins Hospital

Maryland, USA

Topic

Catheter ablation is an antiarrhythmic surgical technique used in the treatment of atrial fibrillation. Typically, it is performed with uninterrupted anticoagulation with warfarin, or interruption of a NOAC course for a period before and following surgery. However, the results of this new study indicate that an uninterrupted course of NOACs may, in fact, be safer than other anticoagulant courses.

View abstract Access full paper

  • Target audience

    This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.

  • Learning objectives

    Upon completion of this activity, participants should be able to:

    • Identify factors that influence the choice and dose of oral anticoagulant in atrial fibrillation patients scheduled to receive an ablation procedure.
  • Disclosures

    Professor John Camm
    Advisor for: Boehringer Ingelheim, Daiichi Sankyo
    Consultant (retained) for: Boehringer Ingelheim
    Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer

    Dr Hugh Calkins
    Consultant for: Boehringer Ingelheim, Medtronic
    Received honoraria from: Boehringer Ingelheim
    Received research support from: Boehringer Ingelheim

    Staff and reviewer disclosures

    PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Funding

    This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme.

    The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the materials or presentations available on this website.